Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

CryoPur DMSO Solutions from OriGen

Products are for professional/laboratory use only.  Sterile filtered dimethyl sulfoxide (DMSO) is available in a variety of packages and volumes designed for lab use. 100% DMSO solutions are packed in polymeric syringes or glass vials.

DMSO sterile filled syringes are fitted with a stopcock and are shipped with the actuator blocked for safety. They are available in multiple volumes for easy, aseptic transfer.

CryoPur 100% DMSO vials are available in 10, 50, 70 and 100ml fill volumes. Caps are flip off/tear off seal.

USP & PH.EUR. Grade

OriGen DMSO products are manufactured using DMSO, Dextran and water for injection certified to USP and PhEur standards. DMSO solutions are sterile, aseptically-filled and non-pyrogenic.

Quality Standards

A Certificate of Analysis (CoA) is available for each DMSO product. OriGen is certified to ISO 13485:2016, MDSAP certified and all products are manufactured to GMP guidelines.

Ordering Information

Product Code

Product Description

Size

OGSP10

DMSO 10ml polymeric syringe

10 units

OGSP20

DMSO 20ml polymeric syringe

10 units

OGSP30

DMSO 30ml polymeric syringe

5 units

OGSP50

DMSO 50ml polymeric syringe

5 units

OGCP10

DMSO 10ml vial with flip cap

12 x 10ml vials

OGCP50

DMSO 50ml vial with flip cap

6 x 50ml vials

OGCP70

DMSO 70ml vial with flip cap

6 x 70ml vials

OGCP100

DMSO 100ml vial with flip cap

6 x 100ml vials


Find out more about OriGen CryoPur

Download Product Flyer >



Request a Quote

Request Quote

Recent Posts

ZytoVision – New ZytoLight Probes

NECTIN4  |  MALT1/IGH  |  TNFRSF14/1q25  |  PLAG1 (more…)

Read full article

ImmunoIVD – Spot-it™ Newborn Screening Assays

ImmunoIVD, Early Detection for Life-Saving interventions Brisbane, Australia – July 31, 2025 (more…)

Read full article

Asuragen – QuantideX ESR1 exoMutation Kit

ESR1 Mutations are the Leading Cause of Primary Treatment Resistance in HR+ mBC ESR1 gene codes for estrogen receptor alpha (ERα), and mutations in its ligand-binding domain…

Read full article